NSCLC — Indication Intelligence | Humanexa Signals

ClinicalJuly 31, 2026

Study of Pembrolizumab Plus MK-1084 in NSCLC with KRAS G12C Mutations

The study aims to evaluate the safety and efficacy of MK-1084 in treating NSCLC patients with KRAS G12C mutations.

ClinicalJuly 30, 2026

Phase 2 Study of Poziotinib in NSCLC with EGFR/HER2 Mutations Underway

A Phase 2 study is evaluating poziotinib's efficacy and safety in NSCLC patients with specific mutations.

ClinicalJuly 29, 2026

Phase II/III Trial of BL-B01D1 with Osimertinib in EGFR-mutant NSCLC Initiated

A Phase II/III trial has been initiated to evaluate BL-B01D1 combined with osimertinib in patients with resectable EGFR-mutant non-small cell lung cancer.

ClinicalJuly 28, 2026

Regeneron initiates trial for ubamatamab and REGN7075 in advanced NSCLC

Regeneron is conducting a study to evaluate the efficacy and safety of ubamatamab and REGN7075 in advanced/metastatic NSCLC.

ClinicalJuly 27, 2026

Study on Firmonertinib for EGFR-mutated NSCLC Adjusted by ctDNA Changes

A prospective study is investigating Firmonertinib as a first-line therapy for EGFR-mutated NSCLC, adapting treatment based on ctDNA changes.

RegulatoryJuly 25, 2026

FDA approves zidesamtinib for ROS1-positive non-small cell lung cancer

The FDA has approved zidesamtinib for adults with ROS1-positive NSCLC after prior TKI treatment.

ClinicalJuly 25, 2026

Narlumosbart with SBRT shows promise in NSCLC with bone metastases in new Phase II trial

A Phase II trial is investigating narlumosbart, RANKL-targeting mAb, combined with SBRT and first-line chemotherapy/immunotherapy in NSCLC patients with bone metastases.

ClinicalJuly 21, 2026

Study on ctDNA's Predictive Value in NSCLC Patients Treated with ICIs

The study evaluates the predictive value of ctDNA in response and relapse for NSCLC patients treated with immune checkpoint inhibitors and targeted therapies.

ClinicalJuly 18, 2026

Mirati's Adagrasib Plus Pembrolizumab Trial for NSCLC Shows Promise

A trial is underway to assess the combination of adagrasib, pembrolizumab, and chemotherapy in KRAS G12C mutated NSCLC.

ClinicalJuly 17, 2026

AstraZeneca's Study on MET Concordance in Treatment-Naïve NSCLC

AstraZeneca is conducting a multicenter study to assess MET concordance and gene profiling in treatment-naïve non-small cell lung cancer (NSCLC).

ClinicalJuly 16, 2026

Phase 1/2 Study of BH-30643 in NSCLC with EGFR/HER2 Mutations Initiated by BlossomHill Therapeutics

BlossomHill Therapeutics has initiated Phase 1/2 study of BH-30643 targeting NSCLC patients with EGFR and/or HER2 mutations.

StrategyJuly 15, 2026

FDA Approves First Generics of Gilotrif (afatinib) Tablets

The FDA has approved the first generic versions of Gilotrif (afatinib) for treating metastatic NSCLC with specific EGFR mutations.

ClinicalJuly 14, 2026

Divarasib Study in Untreated Advanced NSCLC Shows Promise for Safety and Efficacy

A study is underway to evaluate the safety, pharmacokinetics, and activity of divarasib in advanced or metastatic NSCLC.

CompetitiveJuly 14, 2026

Neladalkib (NVL-655) shows promise in Phase 3 trial for ALK-positive NSCLC

Phase 3 study aims to show neladalkib's superiority over alectinib in PFS for ALK-positive NSCLC.

ClinicalJuly 12, 2026

Phase II Trial of Osimertinib for NSCLC with EGFR Exon 20 Mutations

A phase II trial is underway to evaluate the efficacy of osimertinib in patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations.

ClinicalJuly 11, 2026

AI Model Enhances STAS Detection in NSCLC for Improved Diagnostic Accuracy

A deep learning model for detecting spread through air spaces (STAS) in NSCLC shows high accuracy and agreement with pathologists.

CompetitiveJuly 8, 2026

Phase II Study of JS212 Plus JS111 in EGFR-Mutant NSCLC Initiated by Shanghai Junshi Bioscience

A Phase II study is underway to evaluate JS212 in combination with JS111 for advanced NSCLC patients with EGFR mutations.

ClinicalJuly 7, 2026

Janssen's Amivantamab Study in Advanced NSCLC Evaluates Safety and Efficacy

The study aims to assess the safety and efficacy of Amivantamab as a monotherapy and in combination with lazertinib and chemotherapy in advanced NSCLC.

ClinicalJuly 7, 2026

Janssen's Amivantamab and Docetaxel Combo in NSCLC Enters Phase 1/2 Trials

Janssen is conducting Phase 1/2 study to evaluate the combination of amivantamab and docetaxel in metastatic NSCLC patients without oncogenic driver mutations.

ClinicalJuly 5, 2026

Study Compares Induction Plus Consolidation vs. Consolidation-Only in NSCLC Immunotherapy

The study evaluates the efficacy and safety of two immunotherapy sequencing strategies in unresectable stage III NSCLC.

ClinicalJuly 5, 2026

Novel tumor inflammation score predicts outcomes in NSCLC patients treated with pembrolizumab and gemcitabine

A novel tumor inflammation score based on Treg/T cell relationships predicts treatment outcomes better than traditional biomarkers in NSCLC.

ClinicalJuly 4, 2026

BMS initiates trial for Imzokitug in NSCLC with Pumitamig and chemotherapy

Bristol-Myers Squibb is conducting a study to evaluate Imzokitug combined with Pumitamig and PDCT in NSCLC.

ClinicalJuly 3, 2026

Novartis initiates trial for JDQ443 in KRAS G12C-mutated NSCLC

Novartis is evaluating JDQ443 as a first-line treatment for KRAS G12C-mutated NSCLC with low PD-L1 expression.

CompetitiveJuly 3, 2026

Phase Ib/II Trial of Ipilimumab, Nivolumab, and Nogapendekin Alfa in NSCLC

A phase Ib/II trial is underway to evaluate the combination of ipilimumab, nivolumab, and nogapendekin alfa in patients with advanced NSCLC.

ClinicalJuly 3, 2026

Merck's Sacituzumab Tirumotecan and Pembrolizumab Combo Trial in NSCLC Underway

A clinical trial is comparing sacituzumab tirumotecan combined with pembrolizumab to pembrolizumab alone in NSCLC patients.

ClinicalJuly 3, 2026

Pharmacogenomics Trial for Alectinib in NSCLC Examines SNP Impact

A new clinical trial is investigating the impact of ALK and CYP4503A4 gene SNPs on the efficacy and side effects of Alectinib in NSCLC patients.

ClinicalJuly 2, 2026

Bruceine D inhibits STAT3-mediated glycolysis, suppressing NSCLC progression

Bruceine D suppresses non-small-cell lung cancer progression by inhibiting STAT3-mediated glycolysis in vitro and in vivo.

ClinicalJuly 2, 2026

Phase II Trial of Tislelizumab and Surufatinib in Unresectable Stage III NSCLC

A phase II trial is underway to assess the efficacy and safety of hypofractionated chemoradiotherapy combined with tislelizumab and surufatinib in patients with unresectable Stage III NSCLC.

ClinicalJuly 2, 2026

Phase III Trial of Atezolizumab Post-Surgery for Stage I NSCLC Shows Promise

The AASI-NSCLC trial is evaluating atezolizumab's effectiveness in preventing recurrence of stage I NSCLC after surgery.

ClinicalJune 30, 2026

Study on Managing Hyperlipidemia in ALK+ NSCLC Patients on Lorlatinib

A study is underway to evaluate management strategies for hyperlipidemia in patients with ALK-positive NSCLC receiving lorlatinib as first-line treatment.

ClinicalJune 30, 2026

Rucaparib Monoclonal Antibody Trial for Lorlatinib-Induced Hypercholesterolemia in NSCLC

A clinical trial is underway to evaluate recakimab in patients with lorlatinib-induced hypercholesterolemia associated with NSCLC.

ClinicalJune 28, 2026

Gilteritinib Study Launch for ALK-positive NSCLC Patients by Astellas Pharma

Astellas Pharma is initiating a study to evaluate gilteritinib in adults with advanced ALK-positive non-small cell lung cancer (NSCLC) who have stopped responding to ALK inhibitors.

ClinicalJune 28, 2026

BMS's Navlimetostat in NSCLC Trial vs. Placebo and Pembrolizumab

A clinical trial is underway to evaluate Navlimetostat combined with pembrolizumab and chemotherapy in NSCLC patients with MTAP deletion.

ClinicalJune 27, 2026

Merck's Calderasib and Durvalumab Trial for KRAS G12C NSCLC Enters Phase

A clinical trial is investigating the combination of calderasib (MK-1084) and durvalumab in patients with unresected KRAS G12C-mutated NSCLC.

ClinicalJune 27, 2026

SYS6010 in Combination with Anti-PD-(L)-1 for NSCLC: Study Launched

A clinical trial has been initiated to evaluate SYS6010 combined with anti-PD-(L)-1 monoclonal antibody in NSCLC patients.

ClinicalJune 24, 2026

Merck's KEYMAKER-U01 Study Explores Pembrolizumab in NSCLC with Chemotherapy

The KEYMAKER-U01 study investigates pembrolizumab alone and in combination with chemotherapy for NSCLC.

ClinicalJune 24, 2026

Pfizer Reports Phase 3 Results for Sigvotatug Vedotin in NSCLC; No Overall Survival Benefit Observed

The Phase 3 SigVie-002 study of sigvotatug vedotin in previously treated metastatic NSCLC did not show a statistically significant improvement in overall survival compared to docetaxel, although a trend for better outcomes was noted in patients with only one prior therapy.

ClinicalJune 20, 2026

Relevant assets

Relevant companies

Recent signals(45)

Study of Pembrolizumab Plus MK-1084 in NSCLC with KRAS G12C Mutations

Phase 2 Study of Poziotinib in NSCLC with EGFR/HER2 Mutations Underway

Phase II/III Trial of BL-B01D1 with Osimertinib in EGFR-mutant NSCLC Initiated

Regeneron initiates trial for ubamatamab and REGN7075 in advanced NSCLC

Study on Firmonertinib for EGFR-mutated NSCLC Adjusted by ctDNA Changes

FDA approves zidesamtinib for ROS1-positive non-small cell lung cancer

Narlumosbart with SBRT shows promise in NSCLC with bone metastases in new Phase II trial

Study on ctDNA's Predictive Value in NSCLC Patients Treated with ICIs

Mirati's Adagrasib Plus Pembrolizumab Trial for NSCLC Shows Promise

AstraZeneca's Study on MET Concordance in Treatment-Naïve NSCLC

Phase 1/2 Study of BH-30643 in NSCLC with EGFR/HER2 Mutations Initiated by BlossomHill Therapeutics

FDA Approves First Generics of Gilotrif (afatinib) Tablets

Divarasib Study in Untreated Advanced NSCLC Shows Promise for Safety and Efficacy

Neladalkib (NVL-655) shows promise in Phase 3 trial for ALK-positive NSCLC

Phase II Trial of Osimertinib for NSCLC with EGFR Exon 20 Mutations

AI Model Enhances STAS Detection in NSCLC for Improved Diagnostic Accuracy

Phase II Study of JS212 Plus JS111 in EGFR-Mutant NSCLC Initiated by Shanghai Junshi Bioscience

Janssen's Amivantamab Study in Advanced NSCLC Evaluates Safety and Efficacy

Janssen's Amivantamab and Docetaxel Combo in NSCLC Enters Phase 1/2 Trials

Study Compares Induction Plus Consolidation vs. Consolidation-Only in NSCLC Immunotherapy

Novel tumor inflammation score predicts outcomes in NSCLC patients treated with pembrolizumab and gemcitabine

BMS initiates trial for Imzokitug in NSCLC with Pumitamig and chemotherapy

Novartis initiates trial for JDQ443 in KRAS G12C-mutated NSCLC

Phase Ib/II Trial of Ipilimumab, Nivolumab, and Nogapendekin Alfa in NSCLC

Merck's Sacituzumab Tirumotecan and Pembrolizumab Combo Trial in NSCLC Underway

Pharmacogenomics Trial for Alectinib in NSCLC Examines SNP Impact

Bruceine D inhibits STAT3-mediated glycolysis, suppressing NSCLC progression

Phase II Trial of Tislelizumab and Surufatinib in Unresectable Stage III NSCLC

Phase III Trial of Atezolizumab Post-Surgery for Stage I NSCLC Shows Promise

Study on Managing Hyperlipidemia in ALK+ NSCLC Patients on Lorlatinib

Rucaparib Monoclonal Antibody Trial for Lorlatinib-Induced Hypercholesterolemia in NSCLC

Gilteritinib Study Launch for ALK-positive NSCLC Patients by Astellas Pharma

BMS's Navlimetostat in NSCLC Trial vs. Placebo and Pembrolizumab

Merck's Calderasib and Durvalumab Trial for KRAS G12C NSCLC Enters Phase

SYS6010 in Combination with Anti-PD-(L)-1 for NSCLC: Study Launched

Merck's KEYMAKER-U01 Study Explores Pembrolizumab in NSCLC with Chemotherapy

Pfizer Reports Phase 3 Results for Sigvotatug Vedotin in NSCLC; No Overall Survival Benefit Observed

CXCL13-expressing CD4(+) T cells enhance anti-tumor immunity in NSCLC through lymphocyte triad formation

Phase III Trial Evaluates Pembrolizumab Timing in NSCLC Treatment

Phase III Study of Durvalumab + Domvanalimab in Stage III Unresectable NSCLC Initiated

Phase III Trial of Osimertinib and Bevacizumab in EGFR-Mutant Lung Cancer

Calderasib and Pembrolizumab Study in KRAS G12C NSCLC Shows Promising Efficacy

Lilly to present Phase 3 study of Retevmo in RET fusion-positive NSCLC at ASCO 2026

Merck and Gilead Discontinue Phase 3 Study of Trodelvy and KEYTRUDA in NSCLC

Pfizer's LORBRENA CROWN Trial Reports Longest Progression-Free Survival in Advanced NSCLC

Upcoming catalysts

Therapeutic areas

Get signals before the market moves